Surgery Partners has jumped sharply in recent weeks, and with a buyout now agreed, the key issue for readers is whether the current price can be backed up by the cash the business is expected to generate over time. With the stock now close to the proposed acquisition level, the market is effectively putting a specific long term value on those future cash flows.
-
The share price has risen 61.5% over the past month, which puts fresh attention on whether that rapid move lines up with the cash the company can realistically produce in the years ahead.
-
The agreed HealthSpan Partners deal at US$23.50 per share in an all cash transaction sets a clear reference point that may reflect expectations for Surgery Partners future cash generation once it is private.
-
If you'd rather focus on sales, this one's for you. See what Surgery Partners's 0.9x P/S says about the price .
The issue now is whether the cash flows that Surgery Partners can generate justify the price investors see today in light of the proposed acquisition terms.
To see how the HealthSpan buyout price compares with other opportunities focused on cash generation, line this move up against 29 high quality undervalued stocks .
Does Surgery Partners Look Pricey on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash Surgery Partners can return to shareholders over time. Latest twelve month Free Cash Flow sits at about $170.9 million, with the model assuming Surgery Partners moves toward relatively steady and modestly growing free cash generation after an expected $250 million in 2025.
Those cash flow projections imply an intrinsic value that sits meaningfully below the current share price of $23.25, so the DCF suggests the market is asking a richer price than the model supports. Because the HealthSpan Partners buyout offers $23.50 per share in cash, that bid goes a little further than the DCF output and helps explain why some shareholder investigations now question whether public investors are being fully compensated for potential future cash generation. To see how this assessment stacks up against other stocks valued on cash flow, compare Surgery Partners intrinsic worth to. Find out what Surgery Partners could be worth using our Discounted Cash Flow (DCF) estimate .
The Surgery Partners Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Surgery Partners pick up where the valuation puzzle leaves off and spell out which paths for revenue, margins and earnings would need to play out for the shares to be worth materially more or less than today's price. They live on Surgery Partners' Community page and turn a single model output into a set of concrete future conditions so you can track over time whether those underlying assumptions still hold.
Community views on Surgery Partners are now split between those who see more upside in the cash flow story and those who focus on balance sheet and legal risks.
Bull case: roughly fairly valued
"Compounding effects from physician recruitment and de novo facilities, evidenced by 330 new physicians year to date by Q2 2026 whose first year revenue cohorts are about 16% higher than the prior class and who have historically roughly doubled revenue in year two with further double-digit growth in year three, give Surgery Partners an embedded revenue and EBITDA ramp that can build ahead of what single-period same-facility models tend to assume…"
Discover why this Narrative puts Surgery Partners at roughly fairly valued .
Bear case: 66% overvalued
"Although management is emphasizing deleveraging and disciplined capital allocation, elevated net-debt-to-EBITDA of around 7x, an expected US$8 million adjusted earnings headwind from new provider taxes and Medicaid rate cuts, and a slower acquisition pace than the US$200 million annual target together point to a scenario where revenue growth is not enough to prevent further pressure on net margins and overall earnings…"
Explore why this Narrative puts Surgery Partners at 66% overvalued .
Surgery Partners valuation still leaves one crucial piece of the puzzle unresolved
Price tags and cash flow models only tell part of the story. For Surgery Partners, the people steering the business and how they are rewarded can heavily influence where those numbers go next. See who runs Surgery Partners and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SGRY .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
